[go: up one dir, main page]

AR061333A1 - Composiciones de vacuna de la neisseria - Google Patents

Composiciones de vacuna de la neisseria

Info

Publication number
AR061333A1
AR061333A1 ARP070102538A ARP070102538A AR061333A1 AR 061333 A1 AR061333 A1 AR 061333A1 AR P070102538 A ARP070102538 A AR P070102538A AR P070102538 A ARP070102538 A AR P070102538A AR 061333 A1 AR061333 A1 AR 061333A1
Authority
AR
Argentina
Prior art keywords
beta1
gal
glcnac
los
pea
Prior art date
Application number
ARP070102538A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR061333A1 publication Critical patent/AR061333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones de la vacuna de la Neisseria, su elaboracion, y al uso de tales composiciones en medicina. Más particularmente se refiere a procedimientos para fabricar nuevas cepas meningococicas manipuladas las cuales son más adecuadas para la produccion de vacunas de vesículas (o ampollas) de membrana neissérica externa, en particular meningococica. Se describen también procedimientos ventajosos y productos de vacunas en base al uso de vacunas de subunidad LOS (lipooligosacáridos meningococicos) novedosa o de vesícula (o ampolla) de membrana externa meningococica las cuales se han vuelto más seguras y más efectivas para uso en sujetos humanos. Reivindicacion 1: Una composicion inmunogénica que comprende LOS L2 y LOS L3 de cepas neisséricas, en la que el LOS L2 y L3 tiene la estructura (1) y en la que para el LOS L2: R1 = GlcNac(beta1-3)-Gal-, Gal-(beta1-4)-GlcNac(beta1-3)-Gal, o -NeuNac(alfa 2-3)-Gal(Beta1-4)-GlcNac(beta1-3)-Gal-; R2= H, PEA o GIc, R3= PEA, R4= H o OAc, R5 = H, PEA, o Gly y en la que para el LOS L3 R1= GlcNac(beta1-3)-Gal-, Gal-(beta1-4)-GlcNac(beta1-3)-Gal, o -NeuNac(alfa 2-3)-Gal(Beta1-4)-GlcNac(beta1-3)-Gal-; R2= PEA, R3= H, R4= H o OAc, R5 = H, PEA, o Gly. Reivindicacion 2: La composicion inmunogénica de la reivindicacion 1, en la que para el LOS L2 R1 = GlcNac(beta1-3)-Gal-, Gal-(beta1-4)-GlcNac(beta1-3)-Gal, o -NeuNac(alfa 2-3)-Gal(Beta1-4)-GlcNac(beta1-3)-Gal-. Reivindicacion 20: La composicion inmunogénica de las reivindicaciones 1-19, en la que el LOS L2 se aísla a partir de una cepa Neisseria meningitidis A, B, C, W135 o Y. Reivindicacion 21: La composicion inmunogénica de las reivindicaciones 1-20, en la que el LOS L3 se aísla a partir de una cepa Neisseria meningitidis A, B, C, W135 o Y.
ARP070102538A 2006-06-12 2007-06-11 Composiciones de vacuna de la neisseria AR061333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80447506P 2006-06-12 2006-06-12
US80448906P 2006-06-12 2006-06-12

Publications (1)

Publication Number Publication Date
AR061333A1 true AR061333A1 (es) 2008-08-20

Family

ID=38832140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102538A AR061333A1 (es) 2006-06-12 2007-06-11 Composiciones de vacuna de la neisseria

Country Status (12)

Country Link
US (2) US20090123499A1 (es)
EP (2) EP2032161B1 (es)
JP (2) JP5275983B2 (es)
AR (1) AR061333A1 (es)
AT (1) ATE450271T1 (es)
CA (2) CA2654709A1 (es)
CL (1) CL2007001698A1 (es)
DE (1) DE602007003596D1 (es)
ES (2) ES2337309T5 (es)
PE (1) PE20080748A1 (es)
TW (1) TW200817034A (es)
WO (2) WO2007144316A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1748791B1 (en) * 2004-05-11 2010-04-14 De Staat der Nederlanden, vert. door de minister van VWS NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2032161B1 (en) * 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2009016237A2 (en) * 2007-08-02 2009-02-05 Glaxosmithkline Biologicals Sa Molecular typing of neisseria strains by determining the presence of genes involved in lipooligosaccharide (los) biosynthesis
KR20110053314A (ko) * 2008-05-30 2011-05-20 더 유에스에이, 애즈 리프리젠티드 바이 더 세크리터리 오브 더 아미, 온 비하프 오브 월터 리드 아미 수막구균성 다가 천연 외막 소포체 백신, 이의 제조 방법 및 사용 방법
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2430151B1 (fr) 2009-05-14 2014-06-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
WO2010134225A1 (ja) * 2009-05-20 2010-11-25 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
CN102480932B (zh) 2009-09-01 2015-01-14 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
JP2013521770A (ja) * 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2828844C (en) * 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CN103156878A (zh) * 2013-04-11 2013-06-19 天津市园艺工程研究所 一种桑黃多糖opc缓释微囊
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
PL3506935T3 (pl) 2016-09-02 2024-06-10 Sanofi Pasteur, Inc. Szczepionka przeciwko Neisseria meningitidis
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EP3650044A1 (en) * 2018-11-06 2020-05-13 ETH Zürich Anti-glycan vaccines
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP0539492B1 (en) 1990-07-16 2003-06-11 University Of North Carolina At Chapel Hill Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ES2329979T3 (es) 1990-08-23 2009-12-03 The University Of North Carolina At Chapel Hill Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna.
US5371186A (en) 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
US5652211A (en) 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
FR2693465B1 (fr) 1992-07-10 1994-09-02 Aerospatiale Soc Nat Industrielle Procédé de préparation d'un polysilane réticulé par rayonnement ionisant et procédé de fabrication d'un matériau composite à matrice de polysilane.
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
IL134436A0 (en) 1997-08-15 2001-04-30 Univ Utrecht Neisseria lactoferrin binding protein
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9814902D0 (en) 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US6951652B2 (en) 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
DK1535928T3 (da) 1998-10-22 2008-10-20 Univ Montana Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis
JP3595264B2 (ja) 1998-11-03 2004-12-02 デ・スタート・デル・ネーデルランデン・ベルテゲンボールディクト・ドール・デ・ミニステル・バン・ベルジーン・ボルクスゲツォントヘイト・エン・クルトゥール 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
BR0107857A (pt) 2000-01-25 2002-10-29 Univ Queensland Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
CA2493977A1 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US20060073168A1 (en) * 2004-08-11 2006-04-06 Stephens David S Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
JP2008537749A (ja) 2005-04-11 2008-09-25 サノフィ・パスツール Ｌｐｓ解毒のためのポリミキシンｂアナログ
EP2032161B1 (en) * 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines

Also Published As

Publication number Publication date
ES2337309T5 (es) 2013-07-30
EP2032160A2 (en) 2009-03-11
CA2654709A1 (en) 2007-12-21
TW200817034A (en) 2008-04-16
EP2032161A2 (en) 2009-03-11
JP2009539922A (ja) 2009-11-19
WO2007144316A3 (en) 2008-05-02
WO2007144317A2 (en) 2007-12-21
JP5275982B2 (ja) 2013-08-28
ES2390291T3 (es) 2012-11-08
WO2007144316A2 (en) 2007-12-21
DE602007003596D1 (de) 2010-01-14
EP2032160B9 (en) 2011-09-14
US20090246224A1 (en) 2009-10-01
WO2007144317A3 (en) 2008-04-17
CA2654706A1 (en) 2007-12-21
EP2032161B1 (en) 2012-07-11
PE20080748A1 (es) 2008-08-18
ATE450271T1 (de) 2009-12-15
JP2009539923A (ja) 2009-11-19
ES2337309T3 (es) 2010-04-22
JP5275983B2 (ja) 2013-08-28
CL2007001698A1 (es) 2008-01-18
EP2032160B2 (en) 2013-04-03
US20090123499A1 (en) 2009-05-14
EP2032160B1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
AR061333A1 (es) Composiciones de vacuna de la neisseria
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
AU2008291974B2 (en) Influenza antigen delivery vectors and constructs
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
EP3058954A3 (en) Immunogenic compositions and methods
BR0015961A (pt) Antìgeno de neisseria de 85kda
JP2011504486A5 (es)
JP2007533729A5 (es)
AP1690A (en) Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof.
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
RU2005127200A (ru) Менингококковые вакцины для введения через слизистую оболочку
JP2011500662A5 (es)
BRPI0410341A (pt) conjugados de polissacarìdeo-proteìna derivatizados de meningococos multivalente e vacina
AR018717A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA, SU USO, UN PROCESO PARA SU PREPARACIoN, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS.
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
NO20084478L (no) Konjugerte lipidderivater
BRPI0820960B8 (pt) composição, composição farmacêutica, e uso da composição
BR112023003571A2 (pt) Vesículas de membrana externa
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR0316687A (pt) Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares a partir de vesìculas de membrana externa de organismos vivos
NZ580603A (en) Intradermal influenza vaccine
BRPI0515125A (pt) conjugados de polissacarìdeo derivatizado-proteìna multivalentes, meningocócicos e vacina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal